Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody

Immunotherapy for cervical cancer should target high-risk human papillomavirus types 16 and 18, which cause 50% and 20% of cervical cancers, respectively. Here, we describe the construction and characterization of the pBI-11 DNA vaccine via the addition of codon-optimized human papillomavirus 18 (HP...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Shiwen, Ferrall, Louise, Gaillard, Stephanie, Wang, Chenguang, Chi, Wei-Yu, Huang, Chuan-Hsiang, Roden, Richard B. S., Wu, T.-C., Chang, Yung-Nien, Hung, Chien-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845631/
https://www.ncbi.nlm.nih.gov/pubmed/33468698
http://dx.doi.org/10.1128/mBio.03224-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845631/
https://www.ncbi.nlm.nih.gov/pubmed/33468698
http://dx.doi.org/10.1128/mBio.03224-20

Ejemplares similares